Massivemarkets

RCKT

Rocket Pharmaceuticals, Inc. Common Stock

Nasdaq · usd

—-0.05 (-2.05%)
As of 7:47:53 PM EST on Nov 6, 2026 · 15-minute delayed

Stock performance

How Rocket Pharmaceuticals, Inc. Common Stock (RCKT) stock has performed from one day to one year, with its 52-week range.

-0.87%
-$0.02 over 1D
$2.39$2.42$2.46$2.504:15 AM10:45 AM12:35 PM2:30 PM8:00 PM$2.39
1D
-2.05%
1W
-2.25%
1M
-9.32%
YTD
-32.05%
1Y
-24.29%
52-wk range
$2.17 – $5.45

Key statistics

Today's trading snapshot for RCKT: day range, open, previous close, volume and market cap.

Day range
—
Open
—
Prev close
$2.39
Volume
0
Market cap
$261.81M
Shares out
109.77M

Valuation and profitability ratios: P/E, P/S, ROE

Valuation and profitability ratios for Rocket Pharmaceuticals, Inc. Common Stock: P/E, P/S, P/B, ROE and more.

P/E
—
P/S
—
P/B
0.71
P/FCF
—
ROE
-4.7%
ROA
-4.1%
Debt/Equity
0.06
Div yield
0.00%

As of Nov 6, 2026

8-K filings

Material corporate events Rocket Pharmaceuticals, Inc. Common Stock has disclosed to the SEC on Form 8-K.

  • Investor presentationOct 6, 2026

    Additionally, the Company prepared an investor presentation providing certain updates on the Company's Danon Disease Program used in a corporate webinar on October 6, 2026.

  • On September 15, 2026, Rocket Pharmaceuticals, Inc. issued a press release announcing alignment with the U.S. Food and Drug Administration on continued enrollment and dosing and key elements of the global pivotal Phase 2 trial of RP-A501 for the treatment of Danon disease.

  • Executive compensation changeAug 27, 2026

    Pursuant to the Stevens Amendment, if Mr. Stevens' employment is terminated by the Company without Cause or by Mr. Stevens for Good Reason, he is entitled to receive, subject to his execution and non-revocation of a release of claims: (i) a lump sum payment equal to 12 months of his base salary; (ii) any incentive bonus to which he is otherwise entitled for the prior fiscal year; and (iii) a lump sum amount equal to 12 months of COBRA premiums.

  • On August 3, 2026, Rocket Pharmaceuticals, Inc. (the "Company") issued a press release announcing a positive clinical safety update regarding the initial three patients treated under the modified protocol for its global, pivotal Phase 2 trial of RP-A501 in Danon disease.

  • On June 24, 2026, John Militello informed Rocket Pharmaceuticals, Inc. (the "Company" or "Rocket") of his resignation as VP of Finance, Senior Controller, Treasurer and Principal Accounting Officer, effective July 7, 2026, to pursue other opportunities.

RCKT short interest

How heavily RCKT is shorted: shares short, days to cover and average daily volume.

Days to cover
6.7
Short interest
16.28M
Avg volume
2.44M

As of · reported to FINRA twice monthly.

RCKT news

The latest news and headlines about Rocket Pharmaceuticals, Inc. Common Stock (RCKT).

Frequently asked questions

What is the Rocket Pharmaceuticals, Inc. Common Stock (RCKT) stock price today?

Massive provides real-time and historical Rocket Pharmaceuticals, Inc. Common Stock (RCKT) quotes via REST API, WebSocket and MCP.

What is Rocket Pharmaceuticals, Inc. Common Stock?

Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for…

What is the short interest in RCKT?

As of Oct 15, 2026, RCKT has 16.28M shares short and 6.7 days to cover.

What exchange is RCKT listed on?

Rocket Pharmaceuticals, Inc. Common Stock (RCKT) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

Build with AI

Build an analysis of RCKT with your agent

Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.

Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a RCKT analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.

Live market data from the Massive API and MCP.Get a free API key

Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.